Keyword: Herceptin

Roche’s blockbuster cancer trio held their ground so far this year despite biosimilar rivals in the EU, thanks to growth in the U.S. and China.

Roche is teeing up a new use for its breast cancer drug Kadcyla, hoping to gin up sales as Herceptin biosimilars hurtle toward the U.S. market.

An independent panel of FDA advisers endorsed Celltrion’s Rituxan biosimilar, sending the program to the FDA for a final say.

Here is some other vaccine news of note for the week.

Ahead of an FDA panel meeting for Celltrion's Rituxan biosimilar, agency reviewers noted "clinically meaningful differences" between the products.

A Takeda founder descendant blasts the Shire deal, as the company moves its U.S. HQ closer to Shire; Sanofi revamps two global units.

Roche is battling competition from Herceptin biosimilars and has reportedly sued Bioepis over its biosimilar as it heads for the finish line.

With biosimilar versions of its top drugs on the horizon, Roche's Genentech unit is parting ways with 223 staffers in California.

AbbVie has filed for a whopping 247 patent on Humira, an example of how drugmakers try to forestall copycat competition.

Roche's first-half sales climbed 7% to $28.3 billion, their fastest clip in about three years, thanks to stepped-up performance from its newer drugs.